T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	2/5/2002 4:56:58 PM
From: scaram(o)uche	of 2243

an old release, thought it might make a good paste....... Elan announces first U.S. approval for it's NanoCrystal™ technology DUBLIN, IRELAND, August 30, 2000 -- Elan Corporation, plc (NYSE: ELN) ('Elan') today announced that marketing approval from the U.S. Food and Drug Administration ('FDA') for a tablet form of American Home Products Corporation's ('AHP') drug Rapamune® represents the first approval for a drug presentation containing Elan's proprietary NanoCrystal technology. Rapamune is indicated for the prevention of organ rejection in kidney transplant patients and the new tablet provides easier administration and storage than the currently marketed Rapamune oral solution. This tablet presentation was made possible through the application of Elan's NanoCrystal technology for poorly water-soluble drug compounds. This technology is a proprietary system of Elan Pharmaceutical Technologies (EPT), Elan's drug delivery division. Elan will receive revenues from AHP on sales of NanoCrystal formulations of Rapamune. 'This first approval for a formulation containing our NanoCrystal technology is a major achievement for EPT and represents the validation of several years' of diligent scientific effort', said Dr Larry Sternson, President of EPT. 'Over 40% of potential drug products suffer from poor water solubility. This frequently results in potentially important products not reaching the market or achieving their full potential. Today, Elan has several collaborations with major pharmaceutical corporations to develop other products and new formulations using the NanoCrystal technology. We believe that the application of our NanoCrystal technology will ensure the successful development of a large number of these potential pharmaceutical products.' (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next